Identification

Name
Paromomycin
Accession Number
DB01421
Type
Small Molecule
Groups
Approved, Investigational
Description

An oligosaccharide antibiotic produced by various streptomyces. [PubChem]

Structure
Thumb
Synonyms
  • (1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
  • Aminosidin
  • Aminosidine
  • Catenulin
  • Crestomycin
  • Estomycin
  • Hydroxymycin
  • Monomycin a
  • Neomycin e
  • Paromomicina
  • PAROMOMYCIN
  • Paromomycin i
  • Paromomycine
  • Paromomycinum
  • Paucimycin
  • Paucimycinum
  • Zygomycin a1
External IDs
ANTIBIOTIC 503-3 / ANTIBIOTIC SF 767B / R 400 / R-400
Product Ingredients
IngredientUNIICASInChI Key
Paromomycin sulfate845NU6GJPS1263-89-4LJRDOKAZOAKLDU-UDXJMMFXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Humatin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1994-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Paromomycin SulfateCapsule250 mg/1OralHeritage2009-10-22Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralDepartment Of State Health Services, Pharmacy Branch2009-10-22Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralSun Pharmaceutical Industries Limited1997-06-30Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralCentral Texas Community Health Centers2009-10-22Not applicableUs
International/Other Brands
Humatin (Parke Davis (now Pfizer))
Categories
UNII
61JJC8N5ZK
CAS number
7542-37-2
Weight
Average: 615.6285
Monoisotopic: 615.296301173
Chemical Formula
C23H45N5O14
InChI Key
UOZODPSAJZTQNH-LSWIJEOBSA-N
InChI
InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O

Pharmacology

Indication

For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Associated Conditions
Pharmacodynamics

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.

Mechanism of action

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.

TargetActionsOrganism
A30S ribosomal protein S10
inhibitor
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Paromomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Paromomycin.Experimental
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Paromomycin.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Paromomycin.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Paromomycin.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Paromomycin.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Paromomycin.Experimental
AceclofenacThe risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Paromomycin.Approved, Investigational
AcemetacinThe risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Paromomycin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Paromomycin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Paromomycin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Paromomycin.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Paromomycin.Approved
AcetylcholineThe therapeutic efficacy of Acetylcholine can be decreased when used in combination with Paromomycin.Approved
AcetyldigitoxinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Acetyldigoxin.Experimental
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Paromomycin.Experimental
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Paromomycin.Approved, Vet Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Paromomycin.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Paromomycin.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paromomycin.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Alaproclate.Experimental
AlclofenacThe risk or severity of nephrotoxicity can be increased when Alclofenac is combined with Paromomycin.Approved, Withdrawn
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Paromomycin.Experimental
Alendronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Paromomycin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Paromomycin.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Paromomycin.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Paromomycin.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Paromomycin.Investigational
AlminoprofenThe risk or severity of nephrotoxicity can be increased when Alminoprofen is combined with Paromomycin.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Paromomycin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Paromomycin.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paromomycin.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Paromomycin is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Alverine.Approved, Investigational
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Paromomycin.Approved
AmdinocillinThe serum concentration of Paromomycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Paromomycin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Paromomycin.Illicit, Withdrawn
AminophenazoneThe risk or severity of nephrotoxicity can be increased when Aminophenazone is combined with Paromomycin.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Paromomycin.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Paromomycin.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Paromomycin.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paromomycin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Paromomycin.Approved
AmoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Paromomycin.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Paromomycin.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Paromomycin.Approved, Investigational
AmpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Paromomycin.Experimental
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Paromomycin.Approved
AntipyrineThe risk or severity of nephrotoxicity can be increased when Antipyrine is combined with Paromomycin.Approved, Investigational
AntrafenineThe risk or severity of nephrotoxicity can be increased when Antrafenine is combined with Paromomycin.Approved
APD791The risk or severity of adverse effects can be increased when Paromomycin is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Paromomycin.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Paromomycin.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Paromomycin.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Arbekacin.Approved, Investigational
ArdeparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Ardeparin.Approved, Investigational, Withdrawn
ArecolineThe therapeutic efficacy of Arecoline can be decreased when used in combination with Paromomycin.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paromomycin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Paromomycin.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Paromomycin.Approved
AspoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Paromomycin.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Paromomycin.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Paromomycin.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Paromomycin.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Paromomycin.Investigational, Vet Approved
AzapropazoneThe risk or severity of nephrotoxicity can be increased when Azapropazone is combined with Paromomycin.Withdrawn
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Paromomycin.Investigational
AzelastineParomomycin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzidocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azlocillin.Approved
AzosemideThe serum concentration of Paromomycin can be increased when it is combined with Azosemide.Investigational
BacampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Paromomycin.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Paromomycin.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Paromomycin.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Bacitracin.Approved, Vet Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paromomycin.Approved
BalsalazideThe risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Paromomycin.Approved, Investigational
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Paromomycin.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Paromomycin.Illicit
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Paromomycin.Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Paromomycin.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Bekanamycin.Experimental
BemiparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Bemiparin.Approved, Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Paromomycin.Withdrawn
BendazacThe risk or severity of nephrotoxicity can be increased when Bendazac is combined with Paromomycin.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Paromomycin.Withdrawn
BenorilateThe risk or severity of nephrotoxicity can be increased when Benorilate is combined with Paromomycin.Experimental
BenoxaprofenThe risk or severity of nephrotoxicity can be increased when Benoxaprofen is combined with Paromomycin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Paromomycin.Approved, Investigational
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Paromomycin.Approved
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Paromomycin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Paromomycin.Approved, Illicit
BenzydamineThe risk or severity of nephrotoxicity can be increased when Benzydamine is combined with Paromomycin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Paromomycin.Approved
BenzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BethanecholThe therapeutic efficacy of Bethanechol can be decreased when used in combination with Paromomycin.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Paromomycin.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Paromomycin.Investigational
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Paromomycin.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Paromomycin.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Paromomycin.Approved, Investigational
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Paromomycin.Experimental
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Paromomycin is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Paromomycin.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Paromomycin.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Paromomycin.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paromomycin.Approved, Illicit, Investigational
BromfenacThe risk or severity of nephrotoxicity can be increased when Bromfenac is combined with Paromomycin.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Paromomycin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Paromomycin.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Paromomycin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Paromomycin.Approved, Investigational, Withdrawn
BufexamacThe risk or severity of nephrotoxicity can be increased when Bufexamac is combined with Paromomycin.Approved, Experimental
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Paromomycin.Experimental, Illicit
BumadizoneThe risk or severity of nephrotoxicity can be increased when Bumadizone is combined with Paromomycin.Experimental
BumetanideThe serum concentration of Paromomycin can be increased when it is combined with Bumetanide.Approved
BuprenorphineParomomycin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paromomycin.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Paromomycin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paromomycin.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paromomycin.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Paromomycin.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Paromomycin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paromomycin.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Paromomycin.Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Paromomycin.Approved, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Paromomycin.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Paromomycin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Paromomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Paromomycin.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Paromomycin.Approved, Investigational
CarbamoylcholineThe therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Paromomycin.Approved
Carbaspirin calciumThe risk or severity of nephrotoxicity can be increased when Carbaspirin calcium is combined with Paromomycin.Experimental, Investigational
CarbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paromomycin.Approved
CarboplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Paromomycin is combined with Carboplatin.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Paromomycin.Experimental
CarfecillinThe serum concentration of Paromomycin can be decreased when it is combined with Carfecillin.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Paromomycin.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Paromomycin.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Paromomycin.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paromomycin.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Paromomycin.Withdrawn
CarprofenThe risk or severity of nephrotoxicity can be increased when Carprofen is combined with Paromomycin.Approved, Vet Approved, Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Paromomycin.Illicit
CefacetrileThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Paromomycin.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Paromomycin.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Paromomycin.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Paromomycin.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Paromomycin.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Paromomycin.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Paromomycin.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Paromomycin.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Paromomycin.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Paromomycin.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Paromomycin.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Paromomycin.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Paromomycin.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Paromomycin.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Paromomycin.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Paromomycin.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Paromomycin.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Paromomycin.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Paromomycin.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Paromomycin.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Paromomycin.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Paromomycin.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Paromomycin.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Paromomycin.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Paromomycin.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Paromomycin.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Paromomycin.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Paromomycin.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Paromomycin.Approved
CelecoxibThe risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Paromomycin.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Cephalothin Group.Experimental
CerlapirdineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cerlapirdine.Investigational
CertoparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Certoparin.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paromomycin.Approved
CevimelineThe therapeutic efficacy of Cevimeline can be decreased when used in combination with Paromomycin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paromomycin.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paromomycin.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paromomycin.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Paromomycin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paromomycin.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Paromomycin.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Paromomycin.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Paromomycin.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paromomycin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paromomycin.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Paromomycin.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paromomycin.Approved
Choline magnesium trisalicylateThe risk or severity of nephrotoxicity can be increased when Choline magnesium trisalicylate is combined with Paromomycin.Approved
CilansetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cilansetron.Investigational
CimicoxibThe risk or severity of nephrotoxicity can be increased when Cimicoxib is combined with Paromomycin.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Paromomycin.Approved
CisaprideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Paromomycin.Approved
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Paromomycin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Paromomycin is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Paromomycin.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paromomycin.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Paromomycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Paromomycin.Approved, Illicit
Clodronic AcidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Paromomycin.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Paromomycin.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Paromomycin.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paromomycin.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Paromomycin.Approved
ClonixinThe risk or severity of nephrotoxicity can be increased when Clonixin is combined with Paromomycin.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Paromomycin.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paromomycin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Paromomycin.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Paromomycin.Approved, Illicit
CloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Paromomycin.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Paromomycin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Paromomycin.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Paromomycin.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Paromomycin.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Paromomycin.Vet Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Paromomycin.Approved
CyclacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cyclacillin.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paromomycin.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Paromomycin.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Paromomycin.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cyclopentamine.Withdrawn
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Paromomycin.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Paromomycin.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Paromomycin.Approved
DalteparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Dalteparin.Approved
DanaparoidThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Danaparoid.Approved, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paromomycin.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Paromomycin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Paromomycin.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Paromomycin.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Paromomycin.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Paromomycin.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Paromomycin.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Paromomycin.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Paromomycin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paromomycin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Paromomycin.Approved, Investigational
DeslanosideThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paromomycin.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Paromomycin.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paromomycin.Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Paromomycin.Withdrawn
DexibuprofenThe risk or severity of nephrotoxicity can be increased when Dexibuprofen is combined with Paromomycin.Approved, Investigational
DexketoprofenThe risk or severity of nephrotoxicity can be increased when Dexketoprofen is combined with Paromomycin.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paromomycin.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Paromomycin.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Paromomycin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Paromomycin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Paromomycin.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paromomycin.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Paromomycin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Paromomycin.Approved, Illicit
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Paromomycin.Vet Approved
DiclofenacThe risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Paromomycin.Approved, Vet Approved
DicloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Paromomycin.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Paromomycin.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paromomycin.Approved, Illicit
DifenpiramideThe risk or severity of nephrotoxicity can be increased when Difenpiramide is combined with Paromomycin.Experimental
DiflunisalThe risk or severity of nephrotoxicity can be increased when Diflunisal is combined with Paromomycin.Approved, Investigational
DigitoxinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Paromomycin.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Paromomycin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Paromomycin.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paromomycin.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Paromomycin.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Paromomycin.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paromomycin.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paromomycin.Approved, Illicit
DistigmineThe therapeutic efficacy of Distigmine can be decreased when used in combination with Paromomycin.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Paromomycin.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Paromomycin.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Paromomycin.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Paromomycin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Paromomycin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Dotarizine.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Paromomycin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Paromomycin.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Paromomycin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Paromomycin.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Paromomycin.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Paromomycin.Experimental, Illicit
DroxicamThe risk or severity of nephrotoxicity can be increased when Droxicam is combined with Paromomycin.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paromomycin.Approved
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Paromomycin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Paromomycin.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Paromomycin.Investigational
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Paromomycin.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Paromomycin.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Paromomycin.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Paromomycin.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Paromomycin.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paromomycin.Approved, Investigational, Vet Approved
EnoxaparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Enoxaparin.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paromomycin.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Paromomycin.Approved, Investigational
EpibatidineThe therapeutic efficacy of Epibatidine can be decreased when used in combination with Paromomycin.Experimental
EpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Epicillin.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Epinastine.Approved, Investigational
EpirizoleThe risk or severity of nephrotoxicity can be increased when Epirizole is combined with Paromomycin.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Paromomycin is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Paromomycin.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Paromomycin.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Paromomycin.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paromomycin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paromomycin.Approved, Investigational
Etacrynic acidThe serum concentration of Paromomycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Paromomycin.Experimental
EthanolParomomycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paromomycin.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of nephrotoxicity can be increased when Ethenzamide is combined with Paromomycin.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Paromomycin.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paromomycin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paromomycin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paromomycin.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Paromomycin.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paromomycin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Paromomycin.Approved, Illicit
Etidronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Etidronic acid.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Paromomycin.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Paromomycin.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Paromomycin.Approved
EtodolacThe risk or severity of nephrotoxicity can be increased when Etodolac is combined with Paromomycin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of nephrotoxicity can be increased when Etofenamate is combined with Paromomycin.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paromomycin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Paromomycin.Withdrawn
EtoricoxibThe risk or severity of nephrotoxicity can be increased when Etoricoxib is combined with Paromomycin.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Paromomycin.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paromomycin.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Paromomycin.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Paromomycin.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Paromomycin.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paromomycin.Approved
FelbinacThe risk or severity of nephrotoxicity can be increased when Felbinac is combined with Paromomycin.Experimental
FenbufenThe risk or severity of nephrotoxicity can be increased when Fenbufen is combined with Paromomycin.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Paromomycin.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenThe risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Paromomycin.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Paromomycin.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Paromomycin.Vet Approved
FentiazacThe risk or severity of nephrotoxicity can be increased when Fentiazac is combined with Paromomycin.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Paromomycin.Experimental
FeprazoneThe risk or severity of nephrotoxicity can be increased when Feprazone is combined with Paromomycin.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Paromomycin.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Paromomycin.Approved, Investigational
FirocoxibThe risk or severity of nephrotoxicity can be increased when Firocoxib is combined with Paromomycin.Experimental, Vet Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paromomycin.Approved, Investigational
FloctafenineThe risk or severity of nephrotoxicity can be increased when Floctafenine is combined with Paromomycin.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Paromomycin.Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Paromomycin.Experimental
FlucloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paromomycin.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Paromomycin.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Paromomycin.Approved, Illicit
FlunixinThe risk or severity of nephrotoxicity can be increased when Flunixin is combined with Paromomycin.Vet Approved
FlunoxaprofenThe risk or severity of nephrotoxicity can be increased when Flunoxaprofen is combined with Paromomycin.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paromomycin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paromomycin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paromomycin.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of nephrotoxicity can be increased when Flurbiprofen is combined with Paromomycin.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Paromomycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Paromomycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Fluvoxamine.Approved, Investigational
FoscarnetThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Foscarnet.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paromomycin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Paromomycin.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Paromomycin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Paromomycin.Approved, Investigational, Vet Approved
FurosemideThe serum concentration of Paromomycin can be increased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paromomycin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Paromomycin.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Paromomycin.Investigational
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Paromomycin.Approved
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Paromomycin.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Paromomycin.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paromomycin.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Paromomycin.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Paromomycin.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Paromomycin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Paromomycin is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Paromomycin.Investigational
GitoformateThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Gitoformate.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Paromomycin.Approved, Illicit
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Paromomycin.Approved, Investigational, Vet Approved
GranisetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Granisetron.Approved, Investigational
GTS-21The therapeutic efficacy of GTS-21 can be decreased when used in combination with Paromomycin.Investigational
GuacetisalThe risk or severity of nephrotoxicity can be increased when Guacetisal is combined with Paromomycin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paromomycin.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paromomycin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paromomycin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paromomycin.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Paromomycin.Experimental
HeparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Heparin.Approved, Investigational
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Paromomycin.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Paromomycin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Paromomycin.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Paromomycin is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Paromomycin.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paromomycin.Approved
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Paromomycin.Approved, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Paromomycin.Experimental
HydrocodoneParomomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Hydrolyzed Cephalothin.Experimental
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Paromomycin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Paromomycin is combined with Hygromycin B.Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Paromomycin.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Paromomycin.Investigational
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Paromomycin.Approved
IbuproxamThe risk or severity of nephrotoxicity can be increased when Ibuproxam is combined with Paromomycin.Withdrawn
IcosapentThe risk or severity of nephrotoxicity can be increased when Icosapent is combined with Paromomycin.Approved, Nutraceutical
IdalopirdineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Paromomycin.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Paromomycin.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Paromomycin.Investigational
ImidaclopridThe therapeutic efficacy of Imidacloprid can be decreased when used in combination with Paromomycin.Vet Approved
Imidazole salicylateThe risk or severity of nephrotoxicity can be increased when Imidazole salicylate is combined with Paromomycin.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Paromomycin.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Paromomycin.Experimental
Incadronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Incadronic acid.Approved, Investigational
IndalpineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Paromomycin.Investigational
IndobufenThe risk or severity of nephrotoxicity can be increased when Indobufen is combined with Paromomycin.Investigational
IndomethacinThe risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Paromomycin.Approved, Investigational
IndoprofenThe risk or severity of nephrotoxicity can be increased when Indoprofen is combined with Paromomycin.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Paromomycin.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Paromomycin is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Paromomycin.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Paromomycin.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Paromomycin.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paromomycin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paromomycin.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Paromomycin.Approved, Investigational, Withdrawn
IsoxicamThe risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Paromomycin.Withdrawn
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Paromomycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of nephrotoxicity can be increased when Kebuzone is combined with Paromomycin.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paromomycin.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Paromomycin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Paromomycin.Approved, Investigational
KetoprofenThe risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Paromomycin.Approved, Vet Approved
KetorolacThe risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Paromomycin.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Paromomycin.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Paromomycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paromomycin.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Lanatoside C.Experimental
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Paromomycin.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Lasmiditan.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Paromomycin.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paromomycin.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paromomycin.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Paromomycin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Paromomycin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Paromomycin is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Paromomycin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Paromomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Paromomycin is combined with Linezolid.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Paromomycin.Experimental
LobelineThe therapeutic efficacy of Lobeline can be decreased when used in combination with Paromomycin.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Paromomycin.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Paromomycin.Experimental
LofexidineThe therapeutic efficacy of Paromomycin can be increased when used in combination with Lofexidine.Approved, Investigational
LonazolacThe risk or severity of nephrotoxicity can be increased when Lonazolac is combined with Paromomycin.Experimental
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Paromomycin.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Paromomycin.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Paromomycin.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paromomycin.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Paromomycin.Approved
LornoxicamThe risk or severity of nephrotoxicity can be increased when Lornoxicam is combined with Paromomycin.Approved, Investigational
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Paromomycin.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paromomycin.Approved
LoxoprofenThe risk or severity of nephrotoxicity can be increased when Loxoprofen is combined with Paromomycin.Approved, Investigational
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Paromomycin.Investigational
LumiracoxibThe risk or severity of nephrotoxicity can be increased when Lumiracoxib is combined with Paromomycin.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Paromomycin.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Paromomycin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Paromomycin.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Paromomycin is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of nephrotoxicity can be increased when Magnesium salicylate is combined with Paromomycin.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Paromomycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Paromomycin.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Paromomycin.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Paromomycin.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Paromomycin.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Paromomycin.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Paromomycin.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Paromomycin.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paromomycin.Approved
Meclofenamic acidThe risk or severity of nephrotoxicity can be increased when Meclofenamic acid is combined with Paromomycin.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Paromomycin.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Paromomycin.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Paromomycin.Experimental
Mefenamic acidThe risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Paromomycin.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paromomycin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Paromomycin.Experimental, Investigational
MeloxicamThe risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Paromomycin.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Paromomycin.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Paromomycin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Paromomycin.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Paromomycin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paromomycin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Paromomycin.Experimental
MesalazineThe risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Paromomycin.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Paromomycin.Approved, Investigational
MetamizoleThe risk or severity of nephrotoxicity can be increased when Metamizole is combined with Paromomycin.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Metampicillin.Experimental
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paromomycin.Approved
MetergolineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Metergoline.Experimental
MethacholineThe therapeutic efficacy of Methacholine can be decreased when used in combination with Paromomycin.Approved, Investigational
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Paromomycin.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Paromomycin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Paromomycin.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Paromomycin.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Paromomycin.Investigational
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Paromomycin.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paromomycin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Paromomycin.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Paromomycin.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paromomycin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paromomycin.Approved
MethotrimeprazineParomomycin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Paromomycin.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paromomycin.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Paromomycin.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Paromomycin.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Paromomycin.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Paromomycin.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Methysergide.Approved
MeticillinThe serum concentration of Paromomycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Metildigoxin.Experimental
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Paromomycin.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Paromomycin.Approved, Withdrawn
MetyrosineParomomycin may increase the sedative activities of Metyrosine.Approved
MezlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Paromomycin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paromomycin.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Paromomycin.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Paromomycin is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Paromomycin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved, Investigational
MirtazapineParomomycin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Paromomycin.Approved
MK-212The risk or severity of adverse effects can be increased when Paromomycin is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Paromomycin is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paromomycin.Approved, Investigational
MofebutazoneThe risk or severity of nephrotoxicity can be increased when Mofebutazone is combined with Paromomycin.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Paromomycin.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Paromomycin.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Paromomycin.Approved, Investigational, Withdrawn
MorniflumateThe risk or severity of nephrotoxicity can be increased when Morniflumate is combined with Paromomycin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Paromomycin.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Paromomycin.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Paromomycin.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved, Investigational
NabumetoneThe risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Paromomycin.Approved
NadroparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Nadroparin.Approved, Investigational
NafcillinThe serum concentration of Paromomycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Paromomycin is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Paromomycin.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Naluzotan.Investigational
NaproxenThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Paromomycin.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Paromomycin is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Paromomycin.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Paromomycin.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Paromomycin.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Paromomycin.Investigational
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Paromomycin.Approved, Vet Approved
NepafenacThe risk or severity of nephrotoxicity can be increased when Nepafenac is combined with Paromomycin.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Paromomycin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Paromomycin.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Paromomycin.Experimental
NicotineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Nicotine.Approved
NifenazoneThe risk or severity of nephrotoxicity can be increased when Nifenazone is combined with Paromomycin.Experimental
Niflumic AcidThe risk or severity of nephrotoxicity can be increased when Niflumic Acid is combined with Paromomycin.Approved
NimesulideThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Paromomycin.Approved, Investigational, Withdrawn
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Paromomycin.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paromomycin.Approved
NitroaspirinThe risk or severity of nephrotoxicity can be increased when Nitroaspirin is combined with Paromomycin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paromomycin.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Paromomycin.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Paromomycin.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Paromomycin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Paromomycin.Approved
NS-398The risk or severity of nephrotoxicity can be increased when NS-398 is combined with Paromomycin.Experimental
ObidoximeThe therapeutic efficacy of Obidoxime can be decreased when used in combination with Paromomycin.Experimental
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Paromomycin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paromomycin.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Oleandrin.Experimental, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paromomycin.Approved
OlsalazineThe risk or severity of nephrotoxicity can be increased when Olsalazine is combined with Paromomycin.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Paromomycin.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Paromomycin.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Paromomycin.Approved, Illicit
OrphenadrineParomomycin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Paromomycin.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Paromomycin.Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Paromomycin.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Ouabain.Approved
OxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Paromomycin.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Paromomycin.Experimental
OxaprozinThe risk or severity of nephrotoxicity can be increased when Oxaprozin is combined with Paromomycin.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paromomycin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paromomycin.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Paromomycin.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Paromomycin.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paromomycin.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Paromomycin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Paromomycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paromomycin.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Paromomycin.Experimental
OxyphenbutazoneThe risk or severity of nephrotoxicity can be increased when Oxyphenbutazone is combined with Paromomycin.Approved, Withdrawn
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Paromomycin.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Paromomycin.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paromomycin.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Palonosetron.Approved, Investigational
PamidronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Pamidronate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Paromomycin.Approved
ParaldehydeParomomycin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Paromomycin.Approved
ParaoxonThe therapeutic efficacy of Paraoxon can be decreased when used in combination with Paromomycin.Experimental
ParecoxibThe risk or severity of nephrotoxicity can be increased when Parecoxib is combined with Paromomycin.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Paromomycin.Approved
ParnaparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Parnaparin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Paroxetine.Approved, Investigational
PenamecillinThe serum concentration of Paromomycin can be decreased when it is combined with Penamecillin.Experimental
PenbutololThe risk or severity of adverse effects can be increased when Paromomycin is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Paromomycin.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Paromomycin.Experimental
PentamidineThe risk or severity of nephrotoxicity can be increased when Paromomycin is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Paromomycin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paromomycin.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Paromomycin is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Paromomycin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Paromomycin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paromomycin.Approved
PeruvosideThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Paromomycin.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Paromomycin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Paromomycin.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Paromomycin.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Paromomycin.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Paromomycin.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Paromomycin.Experimental
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Paromomycin.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Paromomycin.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Paromomycin.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paromomycin.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Paromomycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Paromomycin.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Paromomycin.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Paromomycin.Approved
PhentermineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Phentermine.Approved, Illicit
PhenylbutazoneThe risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Paromomycin.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Paromomycin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Paromomycin.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.Approved
PilocarpineThe therapeutic efficacy of Pilocarpine can be decreased when used in combination with Paromomycin.Approved, Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Paromomycin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Paromomycin.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Paromomycin.Experimental
PindololThe risk or severity of adverse effects can be increased when Paromomycin is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Paromomycin.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Paromomycin.Approved
PiperacillinThe serum concentration of Paromomycin can be decreased when it is combined with Piperacillin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Paromomycin.Approved, Investigational
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Paromomycin.Approved
PiretanideThe serum concentration of Paromomycin can be increased when it is combined with Piretanide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Paromomycin.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Paromomycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Paromomycin.Approved
PiroxicamThe risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Paromomycin.Approved, Investigational
PirprofenThe risk or severity of nephrotoxicity can be increased when Pirprofen is combined with Paromomycin.Experimental
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Paromomycin.Investigational
PivampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Pivampicillin.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Paromomycin.Withdrawn
PivmecillinamThe serum concentration of Paromomycin can be decreased when it is combined with Pivmecillinam.Approved
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paromomycin.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paromomycin.Approved
PralidoximeThe therapeutic efficacy of Pralidoxime can be decreased when used in combination with Paromomycin.Approved, Vet Approved
PramipexoleParomomycin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of nephrotoxicity can be increased when Pranoprofen is combined with Paromomycin.Experimental, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Paromomycin.Approved, Illicit
PregabalinThe therapeutic efficacy of Paromomycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Paromomycin.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paromomycin.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Paromomycin.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paromomycin.Approved, Investigational, Vet Approved
Procaine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Paromomycin.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paromomycin.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Paromomycin.Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Paromomycin.Approved, Investigational
ProglumetacinThe risk or severity of nephrotoxicity can be increased when Proglumetacin is combined with Paromomycin.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Paromomycin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Paromomycin.Approved, Investigational
PropacetamolThe risk or severity of nephrotoxicity can be increased when Propacetamol is combined with Paromomycin.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Paromomycin.Experimental
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Paromomycin.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Paromomycin.Approved, Investigational
PropicillinThe serum concentration of Paromomycin can be decreased when it is combined with Propicillin.Experimental
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Paromomycin.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Paromomycin.Vet Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Paromomycin.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Paromomycin.Approved, Investigational, Vet Approved
PropyphenazoneThe risk or severity of nephrotoxicity can be increased when Propyphenazone is combined with Paromomycin.Experimental
ProquazoneThe risk or severity of nephrotoxicity can be increased when Proquazone is combined with Paromomycin.Experimental
ProscillaridinThe risk or severity of adverse effects can be decreased when Paromomycin is combined with Proscillaridin.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Paromomycin.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Paromomycin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Paromomycin.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Paromomycin is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Paromomycin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Puromycin.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Paromomycin.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Paromomycin.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Paromomycin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paromomycin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paromomycin.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Paromomycin.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Paromomycin.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Paromomycin.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Paromomycin.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paromomycin.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ramosetron.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Paromomycin.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paromomycin.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Paromomycin.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Paromomycin.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paromomycin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Paromomycin.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Paromomycin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paromomycin.Approved, Investigational
ReviparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ribostamycin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Paromomycin.Approved, Investigational
RisedronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paromomycin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Ritanserin.Investigational
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Paromomycin.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Rizatriptan.Approved
RobenacoxibThe risk or severity of nephrotoxicity can be increased when Robenacoxib is combined with Paromomycin.Experimental, Vet Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Paromomycin.Approved
RofecoxibThe risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Paromomycin.Approved, Investigational, Withdrawn
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Paromomycin.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Paromomycin.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Paromomycin.Vet Approved
RopiniroleParomomycin may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineParomomycin may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Paromomycin.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Paromomycin.Approved
SafinamideThe risk or severity of adverse effects can be increased when Paromomycin is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Paromomycin.Withdrawn
SalicylamideThe risk or severity of nephrotoxicity can be increased when Salicylamide is combined with Paromomycin.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Paromomycin.Approved, Investigational, Vet Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Paromomycin.Approved
SalsalateThe risk or severity of nephrotoxicity can be increased when Salsalate is combined with Paromomycin.Approved
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Paromomycin.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Sarpogrelate.Investigational
SC-236The risk or severity of nephrotoxicity can be increased when SC-236 is combined with Paromomycin.Experimental, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paromomycin.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paromomycin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Paromomycin.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Paromomycin is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Paromomycin.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paromomycin.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Paromomycin.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Paromomycin.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Paromomycin.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Paromomycin.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Paromomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Paromomycin.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Paromomycin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paromomycin.Approved, Investigational
SulbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Paromomycin.Approved
SulindacThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Paromomycin.Approved, Investigational
SulodexideThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Paromomycin.Approved, Investigational
SultamicillinThe serum concentration of Paromomycin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Paromomycin.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Paromomycin.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Sumatriptan.Approved, Investigational
SuprofenThe risk or severity of nephrotoxicity can be increased when Suprofen is combined with Paromomycin.Approved, Withdrawn
SuvorexantParomomycin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of nephrotoxicity can be increased when Suxibuzone is combined with Paromomycin.Experimental
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Paromomycin.Investigational, Withdrawn
TalampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Talampicillin.Experimental
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Paromomycin.Approved, Illicit
TalniflumateThe risk or severity of nephrotoxicity can be increased when Talniflumate is combined with Paromomycin.Approved
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Paromomycin.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Paromomycin.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Paromomycin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paromomycin.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Paromomycin is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paromomycin.Approved, Investigational
TemocillinThe serum concentration of Paromomycin can be decreased when it is combined with Temocillin.Approved, Investigational
TenidapThe risk or severity of nephrotoxicity can be increased when Tenidap is combined with Paromomycin.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Paromomycin.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Paromomycin.Approved
Tenofovir disoproxilThe serum concentration of Tenofovir disoproxil can be increased when it is combined with Paromomycin.Approved, Investigational
TenoxicamThe risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Paromomycin.Approved
TepoxalinThe risk or severity of nephrotoxicity can be increased when Tepoxalin is combined with Paromomycin.Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Paromomycin.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tetraethylammonium.Experimental, Investigational
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Paromomycin.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Paromomycin.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paromomycin.Investigational
ThalidomideParomomycin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paromomycin.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Paromomycin.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paromomycin.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Paromomycin.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paromomycin.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Paromomycin.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Paromomycin.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Paromomycin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Paromomycin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paromomycin.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Paromomycin.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Paromomycin.Approved, Investigational
Tiaprofenic acidThe risk or severity of nephrotoxicity can be increased when Tiaprofenic acid is combined with Paromomycin.Approved
TicarcillinThe serum concentration of Paromomycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Paromomycin.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Paromomycin.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Paromomycin.Experimental
Tiludronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineThe risk or severity of nephrotoxicity can be increased when Tinoridine is combined with Paromomycin.Investigational
TinzaparinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Tinzaparin.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Paromomycin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Paromomycin.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Paromomycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Paromomycin.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paromomycin.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Paromomycin.Approved, Investigational
TolmetinThe risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Paromomycin.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Paromomycin.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Paromomycin.Approved, Investigational
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Paromomycin.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paromomycin.Approved
TorasemideThe serum concentration of Paromomycin can be increased when it is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Paromomycin.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Paromomycin.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paromomycin.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Paromomycin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paromomycin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Paromomycin.Vet Approved
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Paromomycin.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Paromomycin.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Paromomycin.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paromomycin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Paromomycin.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paromomycin.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Paromomycin.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Paromomycin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Paromomycin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paromomycin.Approved
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Paromomycin.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Paromomycin.Approved, Investigational
TropisetronThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tropisetron.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Paromomycin.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Paromomycin is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Vabicaserin.Investigational
ValdecoxibThe risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Paromomycin.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Paromomycin.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Paromomycin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Paromomycin.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Paromomycin.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Paromomycin.Approved
VareniclineThe therapeutic efficacy of Varenicline can be decreased when used in combination with Paromomycin.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Paromomycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Paromomycin.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paromomycin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Paromomycin.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Paromomycin.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Paromomycin.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Paromomycin.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Paromomycin.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Paromomycin.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Paromomycin.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Paromomycin is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Paromomycin.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Paromomycin.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Paromomycin is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paromomycin.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of nephrotoxicity can be increased when Zaltoprofen is combined with Paromomycin.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paromomycin.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Paromomycin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paromomycin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Paromomycin.Vet Approved
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Paromomycin is combined with Zolmitriptan.Approved, Investigational
ZolpidemParomomycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of nephrotoxicity can be increased when Zomepirac is combined with Paromomycin.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paromomycin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paromomycin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Paromomycin.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paromomycin.Approved, Investigational
Food Interactions
  • Take with food.

References

Synthesis Reference

Federico Arcamone, Giuseppe Cassinelli, "Paromomycin derivatives and process for the preparation thereof." U.S. Patent US4021601, issued October, 1967.

US4021601
General References
  1. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58. [PubMed:11587639]
External Links
Human Metabolome Database
HMDB0015490
KEGG Compound
C00832
PubChem Compound
165580
PubChem Substance
46505391
ChemSpider
145115
ChEBI
7934
ChEMBL
CHEMBL370143
Therapeutic Targets Database
DAP000407
PharmGKB
PA164784023
HET
PAR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Paromomycin_sulfate
ATC Codes
A07AA06 — Paromomycin
AHFS Codes
  • 08:30.04 — Amebicides
PDB Entries
1fjg / 1fyp / 1ibk / 1ibl / 1j7t / 1n32 / 1n33 / 1vvj / 1xmo / 1xmq
show 69 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
2CompletedTreatmentCryptosporidiosis infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLeishmaniasis, Cutaneous4
2RecruitingTreatmentPKDL - Post-Kala-Azar Dermal Leishmanioid1
2TerminatedTreatmentLeishmaniasis, Cutaneous2
2, 3RecruitingTreatmentLeishmania Braziliensis Complex / Leishmaniasis, American / Leishmaniasis, Cutaneous / Leishmaniasis; American, Cutaneous1
3CompletedTreatmentLeishmaniasis, Cutaneous1
3CompletedTreatmentVisceral Leishmaniasis5
3RecruitingTreatmentVisceral Leishmaniasis1
4CompletedTreatmentVisceral Leishmaniasis1
Not AvailableAvailableNot AvailableLeishmaniasis, Cutaneous1
Not AvailableCompletedTreatmentTuberculosis, Pulmonary1
Not AvailableCompletedTreatmentVisceral Leishmaniasis1
Not AvailableTerminatedTreatmentCryptosporidiosis infection / Human Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Caraco Pharmaceutical Labs
  • Heritage Pharmaceuticals
  • Kaiser Foundation Hospital
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
CapsuleOral250 mg
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Paromomycin 250 mg capsule5.67USD capsule
Humatin 250 mg capsule2.67USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility79.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-8.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.23ChemAxon
pKa (Strongest Basic)9.94ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area347.32 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity134.24 m3·mol-1ChemAxon
Polarizability60.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4,5-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C5-positions.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
4,5-disubstituted 2-deoxystreptamines
Alternative Parents
O-glycosyl compounds / Disaccharides / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Tetrahydrofurans / 1,2-aminoalcohols / Oxacyclic compounds / Acetals
show 4 more
Substituents
4,5-disubstituted 2-deoxystreptamine / Disaccharide / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Oxane / Tetrahydrofuran
show 16 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
aminoglycoside antibiotic, amino cyclitol glycoside (CHEBI:7934)

Targets

Kind
Protein
Organism
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
Part of the top of the 30S subunit head.
Gene Name
rpsJ
Uniprot ID
Q5SHN7
Uniprot Name
30S ribosomal protein S10
Molecular Weight
11929.82 Da
References
  1. Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [PubMed:19438282]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Konno T, Kurita D, Takahashi T, Muto A, Himeno H: Initiation-shift of trans-translation by aminoglycosides. Nucleic Acids Symp Ser (Oxf). 2004;(48):299-300. [PubMed:17150597]
  4. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988]

Drug created on July 24, 2007 04:03 / Updated on August 15, 2018 09:51